A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VTVT SEC filings page.
vTv Therapeutics Inc. (VTVT) reported $36.8M in revenue over the twelve months to Sep 30, 2026, up 216600.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending drives the business, while recurring operating losses are financed mainly through external capital rather than operating cash.
FY2025 operating cash flow was-$25.3M against a net loss of$27.0M , showing that reported losses closely tracked cash consumption rather than being mainly non-cash. Financing supplied$77.4M alongside that operating cash outflow, making capital raising the main cash source for the period.
The cost structure remains development-led rather than commercial: in FY2024, R&D was
Financing reshaped the balance sheet: equity moved from
Financial Health Signals
We do not publish a peer-relative financial health score for vTv Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
vTv Therapeutics Inc. scores -3.71, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $326.7M against total assets of $89.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
vTv Therapeutics Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
vTv Therapeutics Inc. reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
vTv Therapeutics Inc. reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
vTv Therapeutics Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
vTv Therapeutics Inc.'s EBITDA was -$12.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
vTv Therapeutics Inc. reported a net loss of $11.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
vTv Therapeutics Inc. held $77.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
vTv Therapeutics Inc.'s quarterly ROE was -16.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 4.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
vTv Therapeutics Inc. invested $7.5M in research and development in Q3 2026. This represents an increase of 7.3% from the same quarter a year earlier. Against the prior quarter it is down 14.1%.
Not reported for Q3 2026.
Not reported for Q3 2026.
VTVT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | $36.8Mn/m | $0-100.0% | $0n/m | $0n/m | $0-100.0% | $17Kn/m |
| R&D Expenses | $7.5M+7.3% | $8.8M+113.7% | $9.0M+217.2% | $3.9M+74.9% | $7.0M+117.7% | $4.1M+19.3% | $2.8M+6.8% | $2.2M+4.5% |
| SG&A Expenses | $4.9M+33.1% | $5.2M+42.6% | $4.6M+25.2% | $4.0M+48.7% | $3.7M+12.1% | $3.6M-2.6% | $3.7M-7.7% | $2.7M+4.1% |
| Operating Income | -$12.4Mn/m | -$13.9Mn/m | $23.3Mn/m | -$7.9Mn/m | -$10.7Mn/m | -$7.7Mn/m | -$6.5Mn/m | -$4.9Mn/m |
| EBITDA | -$12.4Mn/m | -$13.9Mn/m | $23.3Mn/m | -$7.9Mn/m | -$10.7Mn/m | -$7.7Mn/m | -$6.5Mn/m | -$4.9Mn/m |
| Interest Expense | N/A | N/A | N/A | N/A | $5Kn/m | N/A | N/A | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0n/m |
| Net Income | -$11.6Mn/m | -$13.1Mn/m | $24.1Mn/m | -$7.1Mn/m | -$8.7Mn/m | -$6.0Mn/m | -$5.1Mn/m | -$3.6Mn/m |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
VTVT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $78.6M-21.0% | $87.6M+231.2% | $98.8M+208.5% | $89.9M+134.9% | $99.5M+130.5% | $26.4M-43.1% | $32.0M-40.9% | $38.3M+247.3% |
| Current Assets | $78.6M-21.0% | $87.6M+232.1% | $98.8M+209.6% | $89.9M+135.9% | $99.5M+131.5% | $26.4M-42.9% | $31.9M-40.8% | $38.1M+257.6% |
| Cash & Equivalents | $77.2M-21.7% | $86.6M+234.2% | $98.1M+215.8% | $88.9M+142.0% | $98.5M+137.0% | $25.9M-43.1% | $31.1M-40.6% | $36.7M+289.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $62K-39.2% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $8.9M-69.2% | $9.0M-62.7% | $8.9M-61.7% | $25.5M+6.2% | $29.0M+14.7% | $24.0M-7.6% | $23.1M-18.0% | $24.0M-32.9% |
| Current Liabilities | $7.0M-30.9% | $7.0M+32.5% | $6.9M+59.4% | $6.6M+27.8% | $10.2M+58.2% | $5.3M-24.2% | $4.3M-51.6% | $5.2M-51.1% |
| Non-Current Liabilities | $1.9M-89.9% | $1.9M-89.6% | $2.0M-89.5% | $18.8M+0.3% | $18.8M-0.2% | $18.7M-1.5% | $18.8M-2.4% | $18.8M-25.2% |
| Total Equity | $69.7M-1.2% | $78.6M+2746.9% | $90.0M+1035.8% | $64.4M+428.2% | $70.5M+370.0% | $2.8M-83.2% | $7.9M-61.9% | $12.2Mn/m |
| Retained Earnings | -$327.2Mn/m | -$315.6Mn/m | -$302.6Mn/m | -$326.7Mn/m | -$319.6Mn/m | -$310.9Mn/m | -$304.8Mn/m | -$299.7Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
VTVT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2Mn/m | -$11.4Mn/m | $9.2Mn/m | -$9.3Mn/m | -$5.2Mn/m | -$5.1Mn/m | -$5.7Mn/m | -$4.8Mn/m |
| Depreciation & Amortization | $1K-50.0% | $1K-66.7% | $1K-88.9% | $2K-90.9% | $2K-90.9% | $3K-87.0% | $9K-59.1% | $22K-4.3% |
| Stock-Based Compensation | $2.0M+95.1% | $1.7M+85.7% | $1.4M+70.7% | N/A | $1.0M+18.1% | $930K+8.3% | $813K+269.5% | N/A |
| Financing Cash Flow | $709K-99.1% | N/A | N/A | -$321Kn/m | $77.8M+3058.9% | -$42Kn/m | $0-100.0% | $0n/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
VTVT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | 63.1% | N/A | N/A | N/A | N/A | -28776.5% |
| Net Margin | N/A | N/A | 65.5% | N/A | N/A | N/A | N/A | -21376.5% |
| Return on Equity | -16.7%-4.3pp | -16.6%+202.3pp | 26.8%+91.1pp | -11.1%+18.7pp | -12.3%+19.5pp | -218.9%-187.5pp | -64.3%-40.9pp | -29.8% |
| Return on Assets | -14.8%-6.0pp | -14.9%+8.0pp | 24.4%+40.3pp | -7.9%+1.6pp | -8.7%+2.3pp | -22.9%-11.7pp | -15.9%-6.9pp | -9.5%+22.1pp |
| Current Ratio | 11.19+1.4x | 12.48+7.5x | 14.36+7.0x | 13.54+6.2x | 9.79+3.1x | 4.98-1.6x | 7.39+1.4x | 7.34+6.3x |
| Liabilities-to-Equity | 0.13-0.3x | 0.11-8.6x | 0.10-2.8x | 0.40-1.6x | 0.41-1.3x | 8.70+7.1x | 2.92+1.6x | 1.96 |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.37+0.4x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| vTv Therapeutics Inc. VTVT | FY2025 | $0 | -$27.0M | N/A | $62.2M | — |
| Coherus Oncology, Inc. CHRS | FY2025 | $42.2M | $168.0M | N/A | $57.1M | 30/100 |
| Tenaya Therapeutics, Inc. TNYA | FY2025 | N/A | -$90.6M | N/A | $65.3M | — |
| Tenax Therapeutics, Inc. TENX | FY2025 | $0 | -$52.6M | N/A | $56.9M | — |
| Coya Therapeutics, Inc. COYA | FY2025 | $7.9M | -$21.2M | N/A | $69.2M | 64/100 |
| TuHURA Biosciences, Inc. HURA | FY2025 | $0 | -$30.1M | N/A | $82.2M | — |
Where vTv Therapeutics Inc. Ranks
Frequently Asked Questions
vTv Therapeutics Inc. (VTVT) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
vTv Therapeutics Inc. (VTVT) revenue declined by 100.0% year-over-year, from $1.0M to $0 in fiscal year 2025.
No, vTv Therapeutics Inc. (VTVT) reported a net loss of $7.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $27.0M.
vTv Therapeutics Inc. (VTVT) had EBITDA of -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
vTv Therapeutics Inc. (VTVT) has a return on equity of -41.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
vTv Therapeutics Inc. (VTVT) recorded an outflow of $25.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
vTv Therapeutics Inc. (VTVT) had $89.9M in total assets as of fiscal year 2025, including both current and long-term assets.
vTv Therapeutics Inc. (VTVT) invested $17.9M in research and development during fiscal year 2025.
vTv Therapeutics Inc. (VTVT) had a current ratio of 13.54 as of fiscal year 2025, which is generally considered healthy.
vTv Therapeutics Inc. (VTVT) had a liabilities-to-equity ratio of 0.40 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
vTv Therapeutics Inc. (VTVT) had a return on assets of -30.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
vTv Therapeutics Inc. (VTVT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $62.2M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
vTv Therapeutics Inc. (VTVT) trades at 1.7x sales, its market capitalization divided by $36.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $62.2M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, vTv Therapeutics Inc. (VTVT) held $88.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $25.3M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
vTv Therapeutics Inc. (VTVT) has an Altman Z-Score of -3.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
vTv Therapeutics Inc. (VTVT) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
vTv Therapeutics Inc. (VTVT) reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
vTv Therapeutics Inc. (VTVT) reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.